Geron Corporation (GERN)

NASDAQ: GERN · IEX Real-Time Price · USD
3.310
0.00 (0.00%)
Mar 28, 2024, 10:53 AM EDT - Market open

Company Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.

It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation
Geron logo
Country United States
Founded 1990
IPO Date Jun 30, 1996
Industry Biotechnology
Sector Healthcare
Employees 141
CEO Dr. John A. Scarlett M.D.

Contact Details

Address:
919 East Hillsdale Boulevard, Suite 250
Foster City, California 94404
United States
Phone (650) 473-7700
Website geron.com

Stock Details

Ticker Symbol GERN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000886744
CUSIP Number 374163103
ISIN Number US3741631036
Employer ID 75-2287752
SIC Code 2834

Key Executives

Name Position
Dr. John A. Scarlett M.D. Chairman of the Board, President and Chief Executive Officer
Dr. Andrew J. Grethlein Ph.D. Executive Vice President and Chief Operating Officer
Michelle J. Robertson Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial and Accounting Officer
Aron Feingold Vice President of Investor Relations and Corporate Communications
Scott Samuels Executive Vice President, Chief Legal Officer and Corporate Secretary
Shannon Odam Senior Vice President and Chief People Officer
Melissa A. Kelly Behrs Executive Vice President of Business Operations and Chief Alliance Officer
Anil Kapur Executive Vice President of Corporate Strategy and Chief Commercial Officer
Edward E. Koval Executive Vice President and Chief Business Officer
Dr. Faye Feller M.D. Executive Vice President and Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 27, 2024 ARS Filing
Mar 27, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 27, 2024 DEF 14A Other definitive proxy statements
Mar 20, 2024 8-K Current Report
Mar 20, 2024 424B5 Filing
Mar 19, 2024 8-K Current Report
Mar 14, 2024 8-K Current Report
Feb 28, 2024 10-K Annual Report
Feb 28, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals